These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25001304)

  • 1. Cysticidal activity of antifungals against different genotypes of Acanthamoeba.
    Iovieno A; Miller D; Ledee DR; Alfonso EC
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5626-8. PubMed ID: 25001304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy Testing of Antiamoebic Agents for Acanthamoeba: Antagonistic Effect of Voriconazole.
    Talbott M; Cevallos V; Chen MC; Chin SA; Lalitha P; Seitzman GD; Lietman TM; Keenan JD
    Cornea; 2019 Oct; 38(10):1309-1313. PubMed ID: 31306283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against Acanthamoeba castellanii.
    Shing B; Singh S; Podust LM; McKerrow JH; Debnath A
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of isavuconazole against three species of Acanthamoeba.
    Brunet K; Eestermans R; Rodier MH; Cateau E
    J Fr Ophtalmol; 2020 Apr; 43(4):330-333. PubMed ID: 32151474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity.
    Mafra CS; Carrijo-Carvalho LC; Chudzinski-Tavassi AM; Taguchi FM; Foronda AS; Carvalho FR; de Freitas D
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6363-72. PubMed ID: 23900604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole as a first-line treatment against potentially pathogenic Acanthamoeba strains from Peru.
    Cabello-Vílchez AM; Martín-Navarro CM; López-Arencibia A; Reyes-Batlle M; Sifaoui I; Valladares B; Piñero JE; Lorenzo-Morales J
    Parasitol Res; 2014 Feb; 113(2):755-9. PubMed ID: 24265059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of voriconazole anti-Acanthamoeba polyphaga in vitro activity, rat cornea penetration and efficacy against experimental rat Acanthamoeba keratitis.
    Gueudry J; Le Goff L; Compagnon P; Lefevre S; Colasse E; Aknine C; Duval F; François A; Razakandrainibe R; Ballet JJ; Muraine M; Favennec L
    J Antimicrob Chemother; 2018 Jul; 73(7):1895-1898. PubMed ID: 29596605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.
    Martín-Navarro CM; López-Arencibia A; Arnalich-Montiel F; Valladares B; Piñero JE; Lorenzo-Morales J
    Graefes Arch Clin Exp Ophthalmol; 2013 Sep; 251(9):2111-7. PubMed ID: 23686225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a practical complete-kill assay to evaluate anti-Acanthamoeba drugs.
    Kowalski RP; Abdel Aziz S; Romanowski EG; Shanks RM; Nau AC; Raju LV
    JAMA Ophthalmol; 2013 Nov; 131(11):1459-62. PubMed ID: 24077460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri.
    Schuster FL; Guglielmo BJ; Visvesvara GS
    J Eukaryot Microbiol; 2006; 53(2):121-6. PubMed ID: 16579814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the sensitivity to chlorhexidine, voriconazole and itraconazole of T4 genotype Acanthamoeba isolated from Mexico.
    Hernández-Martínez D; Reyes-Batlle M; Castelan-Ramírez I; Hernández-Olmos P; Vanzzini-Zago V; Ramírez-Flores E; Sifaoui I; Piñero JE; Lorenzo-Morales J; Omaña-Molina M
    Exp Parasitol; 2019 Feb; 197():29-35. PubMed ID: 30648558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of In Vitro Antiamoebic Activity of Antimicrobial Agents Against Clinical Acanthamoeba Isolates.
    Nakaminami H; Tanuma K; Enomoto K; Yoshimura Y; Onuki T; Nihonyanagi S; Hamada Y; Noguchi N
    J Ocul Pharmacol Ther; 2017 Oct; 33(8):629-634. PubMed ID: 28704121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acanthamoeba keratitis in Mexico: Report of a clinical case and importance of sensitivity assays for a better outcome.
    Omaña-Molina M; Vanzzini-Zago V; Hernández-Martínez D; Reyes-Batlle M; Castelan-Ramírez I; Hernández-Olmos P; Salazar-Villatoro L; González-Robles A; Ramírez-Flores E; Servín-Flores C; Flores-Alvarado V; Alcántara-Castro M; Lorenzo-Morales J
    Exp Parasitol; 2019 Jan; 196():22-27. PubMed ID: 30472333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial effect of auranofin against Acanthamoeba spp.
    Loufouma Mbouaka A; Leitsch D; Koehsler M; Walochnik J
    Int J Antimicrob Agents; 2021 Nov; 58(5):106425. PubMed ID: 34419578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of antimicrobial compounds for cysticidal activity against Acanthamoeba.
    Osato MS; Robinson NM; Wilhelmus KR; Jones DB
    Rev Infect Dis; 1991; 13 Suppl 5():S431-5. PubMed ID: 2047690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of standardized methods for assessing biocidal efficacy of contact lens care solutions against Acanthamoeba trophozoites and cysts.
    Kilvington S; Lam A
    Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4527-37. PubMed ID: 23745008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluations of topical agents to treat Acanthamoeba keratitis.
    Sunada A; Kimura K; Nishi I; Toyokawa M; Ueda A; Sakata T; Suzuki T; Inoue Y; Ohashi Y; Asari S; Iwatani Y
    Ophthalmology; 2014 Oct; 121(10):2059-65. PubMed ID: 24880905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-isolation of Vahlkampfia and acanthamoeba in acanthamoeba-like keratitis in a Spanish population.
    Arnalich-Montiel F; Lorenzo-Morales J; Irigoyen C; Morcillo-Laiz R; López-Vélez R; Muñoz-Negrete F; Piñero JE; Valladares B
    Cornea; 2013 May; 32(5):608-14. PubMed ID: 22929156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine.
    Narasimhan S; Madhavan HN; K LT
    Cornea; 2002 Mar; 21(2):203-5. PubMed ID: 11862096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis.
    Elder MJ; Kilvington S; Dart JK
    Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):1059-64. PubMed ID: 8125716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.